Loading...
•
Dec 31, 2025
Caribou Biosciences Q4 2025 Earnings Report
Caribou Biosciences reported increased licensing revenue and a narrower quarterly net loss while reducing operating expenses in Q4 2025.
Key Takeaways
Caribou Biosciences generated $3941000 in licensing and collaboration revenue in the fourth quarter of 2025 while reporting a net loss of $26488000. Operating expenses declined year over year as research and development and general administrative spending decreased following workforce reductions and pipeline prioritization.
Licensing and collaboration revenue reached $3941000 in Q4 2025.
Net loss improved to $26488000 compared with $35490000 in Q4 2024.
Research and development expenses were reduced to $23815000.
Total operating expenses declined to $32394000 during the quarter.
Revenue by Segment
Forward Guidance
Caribou expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027 while advancing key CAR-T programs and preparing for a potential pivotal trial for vispa-cel.
Positive Outlook
- Cash runway expected to fund operations into the second half of 2027.
- Dose expansion underway for the CB-011 phase 1 CaMMouflage trial.
- Continued engagement with FDA regarding pivotal vispa-cel trial design.
- Additional clinical data expected in 2026 from ongoing trials.
- Strategic pipeline prioritization has reduced operating expenses.
Challenges Ahead
- Company continues to generate significant net losses.
- Cash balance declined substantially year over year.
- Future funding may be required to fully support pivotal vispa-cel trial.
- Clinical development timelines and regulatory outcomes remain uncertain.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...